Skip header and navigation

Refine By

20 records – page 1 of 2.

677 C-->T polymorphism of the methylenetetrahydrofolate reductase gene and preeclampsia.

https://arctichealth.org/en/permalink/ahliterature197794
Source
Obstet Gynecol. 2000 Aug;96(2):277-80
Publication Type
Article
Date
Aug-2000
Author
H. Laivuori
R. Kaaja
O. Ylikorkala
T. Hiltunen
K. Kontula
Author Affiliation
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland. hannele.laivuori@pp.fimnet.fi
Source
Obstet Gynecol. 2000 Aug;96(2):277-80
Date
Aug-2000
Language
English
Publication Type
Article
Keywords
Adult
Alleles
Amino Acid Substitution
Case-Control Studies
DNA Primers
Female
Finland
Gene Expression Regulation, Enzymologic
Gene Frequency
Genotype
Heterozygote
Humans
Methylenetetrahydrofolate Reductase (NADPH2)
Oxidoreductases Acting on CH-NH Group Donors - genetics
Polymerase Chain Reaction
Polymorphism, Genetic
Pre-Eclampsia - enzymology - genetics
Pregnancy
Abstract
To evaluate C to T substitution at nucleotide 677 of N(5), N(10)-methylenetetrahydrofolate reductase gene in women with prior preeclamptic or normotensive pregnancies.
Methylenetetrahydrofolate reductase genotypes were determined in 113 Finnish women with preeclamptic first pregnancies and 103 controls with one or more normotensive pregnancies, using polymerase chain reaction and restriction enzyme analysis. Preeclampsia was defined as severe in 100 women who fulfilled one or more of the subsequent criteria: systolic blood pressure (BP) at least 160 mmHg, diastolic BP at least 110 mmHg, or proteinuria at least 2 g per 24-hour urine collection.
There were no significant differences in prevalences of the methylenetetrahydrofolate reductase genotypes (CC, CT, and TT) between groups (57%, 40%, and 3% in the preeclamptic group and 54%, 39%, and 7%, respectively, in controls). The frequency of the T677 allele was 0.23 in the preeclamptic group and 0.26 in the control group (difference 0.03; 95% confidence interval -0.08, 0.14; P =.51). Our sample had 60% power to detect a difference of the allele frequencies similar to that (0.12) reported previously. The result was similar when analysis was restricted to patients with severe preeclampsia (T677 allele frequency 0.22).
A carrier status for the T677 allele of the methylenetetrahydrofolate reductase gene does not predispose to preeclampsia, at least in the Finnish population.
PubMed ID
10908777 View in PubMed
Less detail

Association of a common allelic polymorphism (C677T) in the methylene tetrahydrofolate reductase gene with a reduced risk of osteoporotic fractures. A case control study in Danish postmenopausal women.

https://arctichealth.org/en/permalink/ahliterature188538
Source
Calcif Tissue Int. 2002 Nov;71(5):386-92
Publication Type
Article
Date
Nov-2002
Author
H L Jørgensen
J S Madsen
B. Madsen
M M A Saleh
B. Abrahamsen
M. Fenger
J B Lauritzen
Author Affiliation
Department of Clinical Biochemistry, Hvidovre University Hospital, Kettegaard Allé 30, 2650 Hvidovre, Denmark. HLJ@Dadlnet.dk
Source
Calcif Tissue Int. 2002 Nov;71(5):386-92
Date
Nov-2002
Language
English
Publication Type
Article
Keywords
Aged
Alleles
Bone Density
Calcaneus - ultrasonography
Case-Control Studies
DNA - analysis
DNA Mutational Analysis
Denmark
Female
Forearm Injuries - diagnosis - enzymology - genetics
Genetic Predisposition to Disease
Hip Fractures - diagnosis - enzymology - genetics
Humans
Methylenetetrahydrofolate Reductase (NADPH2)
Middle Aged
Mutation
Odds Ratio
Osteoporosis, Postmenopausal - diagnosis - enzymology - genetics
Oxidoreductases Acting on CH-NH Group Donors - genetics
Polymerase Chain Reaction
Polymorphism, Genetic
Risk factors
Abstract
Twin studies indicate a substantial genetic component in the development of osteoporosis. One of the latest studied candidate genes is the one coding for methylene tetrahydrofolate reductase (MTHFR) (C677T) in which a point mutation gives rise to a thermolabile variant of MTHFR. The aim of this study was to investigate the influence of this mutation on peripheral measures of bone density and on the odds ratios (OR) for hip and lower forearm fracture in a case control study of Danish postmenopausal women. A total of 74 women with lower forearm fracture, 41 women with hip fracture, and 207 age-matched controls were included. All had broadband ultrasound attenuation (BUA) and speed of sound (SOS) measured at the heel as well as bone mineral density (BMD) measured by dual X-ray absorptiometry at the distal forearm. The MTHFR (C677T) genotypes were determined using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Only 2 of 21 individuals with the TT genotype had sustained a fracture as opposed to 46 of 142 with the CT genotype and 67 of 159 with the CC genotype (P = 0.007). Using logistic regression, the following odds ratios were found when comparing the individuals homozygotic for the C-allele with those homozygotic for the T-allele: lower forearm fracture OR = 3.93 (1.25; 12.40, P = 0.02), hip fracture OR = 6.99 (l.35; 36.92, P = 0.02) and the fractures combined OR = 4.33 (1.73; 10.81, P = 0.002). In this study, the MTHFR (C677T) genotypes were not significantly associated with BMD at the lower forearm or with ultrasound parameters measured at the calcaneus. However, a significant increase in the odds ratio of fracture was found for the wild-type C-allele.
PubMed ID
12232679 View in PubMed
Less detail

Association of polyaminergic loci with anxiety, mood disorders, and attempted suicide.

https://arctichealth.org/en/permalink/ahliterature138657
Source
PLoS One. 2010;5(11):e15146
Publication Type
Article
Date
2010
Author
Laura M Fiori
Brigitte Wanner
Valérie Jomphe
Jordie Croteau
Frank Vitaro
Richard E Tremblay
Alexandre Bureau
Gustavo Turecki
Author Affiliation
McGill Group for Suicide Studies, Douglas Mental Health University Institute, McGill University, Montreal, Quebec, Canada.
Source
PLoS One. 2010;5(11):e15146
Date
2010
Language
English
Publication Type
Article
Keywords
Acetyltransferases - genetics
Anxiety Disorders - genetics - psychology
Canada
France - ethnology
Gene Frequency
Genetic Predisposition to Disease - genetics - psychology
Genotype
Haplotypes
Humans
Mood Disorders - genetics - psychology
Multivariate Analysis
Odds Ratio
Ornithine-Oxo-Acid Transaminase - genetics
Oxidoreductases Acting on CH-NH Group Donors - genetics
Polyamines - metabolism
Polymorphism, Single Nucleotide
Spermine Synthase - genetics
Suicide, Attempted
Abstract
The polyamine system has been implicated in a number of psychiatric conditions, which display both alterations in polyamine levels and altered expression of genes related to polyamine metabolism. Studies have identified associations between genetic variants in spermidine/spermine N1-acetyltransferase (SAT1) and both anxiety and suicide, and several polymorphisms appear to play important roles in determining gene expression.
We genotyped 63 polymorphisms, spread across four polyaminergic genes (SAT1, spermine synthase (SMS), spermine oxidase (SMOX), and ornithine aminotransferase like-1 (OATL1)), in 1255 French-Canadian individuals who have been followed longitudinally for 22 years. We assessed univariate associations with anxiety, mood disorders, and attempted suicide, as assessed during early adulthood. We also investigated the involvement of gene-environment interactions in terms of childhood abuse, and assessed internalizing and externalizing symptoms as endophenotypes mediating these interactions. Overall, each gene was associated with at least one main outcome: anxiety (SAT1, SMS), mood disorders (SAT1, SMOX), and suicide attempts (SAT1, OATL1). Several SAT1 polymorphisms displayed disease-specific risk alleles, and polymorphisms in this gene were involved in gene-gene interactions with SMS to confer risk for anxiety disorders, as well as gene-environment interactions between childhood physical abuse and mood disorders. Externalizing behaviors demonstrated significant mediation with regards to the association between OATL1 and attempted suicide, however there was no evidence that externalizing or internalizing behaviors were appropriate endophenotypes to explain the associations with mood or anxiety disorders. Finally, childhood sexual abuse did not demonstrate mediating influences on any of our outcomes.
These results demonstrate that genetic variants in polyaminergic genes are associated with psychiatric conditions, each of which involves a set of separate and distinct risk alleles. As several of these polymorphisms are associated with gene expression, these findings may provide mechanisms to explain the alterations in polyamine metabolism which have been observed in psychiatric disorders.
Notes
Cites: Am J Med Genet B Neuropsychiatr Genet. 2003 Apr 1;118B(1):36-4012627464
Cites: Epidemiol Psichiatr Soc. 2009 Jan-Mar;18(1):23-3319378696
Cites: Cell Mol Neurobiol. 2003 Oct;23(4-5):637-4914514021
Cites: Psychol Med. 2003 Oct;33(7):1299-30914580083
Cites: Eur J Hum Genet. 2003 Dec;11(12):937-4414508504
Cites: Nature. 2003 Dec 18;426(6968):789-9614685227
Cites: Psychol Rep. 1974 Apr;34(2):445-64820501
Cites: Psychol Med. 1982 Nov;12(4):855-707156256
Cites: J Pers Soc Psychol. 1986 Dec;51(6):1173-823806354
Cites: Am J Med Genet B Neuropsychiatr Genet. 2009 Jun 5;150B(4):515-918759322
Cites: Biol Psychiatry. 2009 Sep 1;66(5):460-719446796
Cites: Am J Med Genet B Neuropsychiatr Genet. 2009 Sep 5;150B(6):799-80719051286
Cites: Am J Med Genet B Neuropsychiatr Genet. 2009 Oct 5;150B(7):934-4319152344
Cites: Neurogenetics. 2009 Oct;10(4):299-30519277733
Cites: Am J Psychiatry. 2009 Oct;166(10):1124-3419755577
Cites: Depress Anxiety. 2009;26(11):1004-1119750555
Cites: Am J Med Genet B Neuropsychiatr Genet. 2010 Apr 5;153B(3):825-919851986
Cites: PLoS One. 2010;5(4):e997020376317
Cites: Neuropsychopharmacology. 2010 Jun;35(7):1477-8420200507
Cites: Int J Neuropsychopharmacol. 2010 Jul;13(6):725-3620059804
Cites: Mol Psychiatry. 2010 Aug;15(8):831-4319381154
Cites: Psychol Med. 2000 Jan;30(1):23-3910722173
Cites: Trends Pharmacol Sci. 2000 May;21(5):187-9310785653
Cites: J Pediatr Psychol. 2002 Jan-Feb;27(1):87-9611726683
Cites: Crisis. 2001;22(2):61-511727895
Cites: Am J Hum Genet. 2002 Feb;70(2):425-3411791212
Cites: Genet Epidemiol. 2001;21 Suppl 1:S18-2311793665
Cites: Psychol Med. 2002 Jan;32(1):11-2411883722
Cites: Mol Psychiatry. 2011 Feb;16(2):216-2620010893
Cites: J Abnorm Child Psychol. 1991 Jun;19(3):285-3001865046
Cites: Psychol Bull. 1993 Sep;114(2):376-908416037
Cites: Hum Mol Genet. 1994 Mar;3(3):459-638012358
Cites: Am J Hum Genet. 1995 Apr;56(4):970-87717408
Cites: Am J Prev Med. 1998 May;14(4):245-589635069
Cites: Psychol Med. 1998 Jul;28(4):839-559723140
Cites: J Am Acad Child Adolesc Psychiatry. 1998 Nov;37(11):1167-749808928
Cites: BMC Psychiatry. 2004;4:3715527502
Cites: Arch Gen Psychiatry. 2005 Jan;62(1):29-3615630070
Cites: Genet Epidemiol. 2005 Apr;28(3):193-20615637716
Cites: Am J Psychiatry. 2005 May;162(5):1017-915863812
Cites: J Cell Mol Med. 2005 Jul-Sep;9(3):623-4216202210
Cites: Nat Genet. 2005 Nov;37(11):1217-2316244653
Cites: J Psychiatry Neurosci. 2005 Nov;30(6):398-40816327873
Cites: Arch Gen Psychiatry. 2006 Jan;63(1):35-4816389195
Cites: Biol Psychiatry. 2006 Jul 15;60(2):84-9216300747
Cites: Pac Symp Biocomput. 2006;:487-9817094263
Cites: J Clin Psychiatry. 2007 May;68(5):721-917503981
Cites: Mol Psychiatry. 2007 Jul;12(7):640-5517353912
Cites: Psychol Med. 2007 Nov;37(11):1563-7417927844
Cites: Schizophr Res. 2008 Jan;98(1-3):217-2417942279
Cites: J Psychiatry Neurosci. 2008 Mar;33(2):102-1018330456
Cites: Psychiatr Clin North Am. 2008 Jun;31(2):179-20318439443
Cites: Br J Psychiatry. 2008 Aug;193(2):134-918669998
Cites: J Med Genet. 2008 Aug;45(8):539-4318550699
Cites: Epidemiol Rev. 2008;30:133-5418653727
Cites: Arch Pediatr Adolesc Med. 2008 Nov;162(11):1015-2118981348
Cites: Mol Psychiatry. 2009 Feb;14(2):175-8917938633
Cites: Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):345-819162121
Cites: Am J Med Genet A. 2009 Mar;149A(3):328-3519206178
Cites: Genet Epidemiol. 2003 Sep;25(2):115-2112916020
PubMed ID
21152090 View in PubMed
Less detail

[C677T mutation in methylentetrahydrofolatereductase gene in patients with venous thromboses from the central region of Russia correlates with a high risk of pulmonary artery thromboembolism].

https://arctichealth.org/en/permalink/ahliterature168072
Source
Ter Arkh. 2006;78(6):70-6
Publication Type
Article
Date
2006
Author
P V Avdonin
A I Kirienko
L M Kozhevnikova
N A Shostak
N M Babadaeva
S G Leont'ev
E B Petukhov
A A Kubatiev
V S Savel'ev
Source
Ter Arkh. 2006;78(6):70-6
Date
2006
Language
Russian
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Catchment Area (Health)
Factor V
Female
Gene Frequency
Genetic Predisposition to Disease
Humans
Male
Methylenetetrahydrofolate Reductase (NADPH2) - genetics
Middle Aged
Oxidoreductases Acting on CH-NH Group Donors - genetics
Point Mutation - genetics
Prothrombin - genetics
Pulmonary Embolism - genetics
Risk assessment
Russia
Abstract
To investigate genetic factors of risk (RF) to develop venous thrombosis and pulmonary artery thromboembolism (PATE) in population of central Russia.
We studied polymorphism of the genes of coagulation factor II (G20210A), factor V (G1691A) and methylentetrahydrofolatereductase (MTHFR) with polymerase chain reaction and restriction analysis of DNA amplified sites. We estimated prevalence of the mutations in healthy population and in patients with flebothrombosis as well as effects of the mutations on a PATE rate in patients with thrombosis. We examined 97 patients with documented flebothrombosis. PATE was detected in 54 of them. The control group consisted of 56 healthy volunteers matched by age and gender.
G1691A mutation in the gene of coagulation factor V (Leiden mutation of factor V--LMFV) in healthy population occurred in 3.6%, in patients with flebothromboses--in 19.6% (OR = 6.58; 95% CI from 1.47 to 29.42; p = 0.006). Heterozygous mutation G20210A in prothrombine gene was detected in 8 (8.2%) patients (p = 0.027), while this mutation was registered in none controls. Polymorphism of MTHFR gene (C677T) was seen both in the control and patients (60.7 and 52.6%, respectively). LMFV occurrence in patients with flebothrombosis and PATE is less than in patients with flebothrombosis without TEPA (16.7 and 23%, respectively). The PATE risk is significantly higher in carriers of mutant allele 677CT and 677TT of MTHFR compared to patients free of this mutation (OR = 3.11; CI 95% from 1.35 to 7.15; p = 0.006). Homozygous inheritance of this mutation in males combined with PATE in 100% cases. Of 8 carriers of heterozygous mutation G20210A in prothrombin gene PATE was detected in 5 carriers.
LMFV and mutation G20210A in prothrombin gene are genetic risk factors of venous thrombosis. LMFV is not a PATE risk factor. Mutation C677T in MTHFR gene has no influence on the risk of venous thromboses but makes PATE much more probable. This suggests that it may be a genetic risk factor of PATE in this disease.
PubMed ID
16881367 View in PubMed
Less detail

A common methylenetetrahydrofolate reductase gene mutation and longevity.

https://arctichealth.org/en/permalink/ahliterature58924
Source
Atherosclerosis. 1998 Dec;141(2):315-9
Publication Type
Article
Date
Dec-1998
Author
L. Brattström
Y. Zhang
M. Hurtig
H. Refsum
S. Ostensson
L. Fransson
K. Jonés
F. Landgren
L. Brudin
P M Ueland
Author Affiliation
Department of Medicine, County Hospital, Kalmar, Sweden. lars.brattstrom@alinks.se
Source
Atherosclerosis. 1998 Dec;141(2):315-9
Date
Dec-1998
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Cardiovascular Diseases - etiology - genetics - mortality
Female
Gene Frequency
Genotype
Homozygote
Humans
Hyperhomocysteinemia - complications - genetics
Infant, Newborn
Longevity - genetics
Male
Methylenetetrahydrofolate Reductase (NADPH2)
Mutation
Odds Ratio
Oxidoreductases Acting on CH-NH Group Donors - genetics
Research Support, Non-U.S. Gov't
Risk factors
Sweden
Abstract
Homozygotes (TT genotype) for the C677T mutation in the gene of methylenetetrahydrofolate reductase (C677T/MTHFR mutation) constitute about 12% of the Caucasian population. They have mild hyperhomocysteinemia which is an established risk factor for cardiovascular disease. If the mutation is associated with premature death its prevalence is expected to be lower in the elderly than in the young. To test this we determined the C677T/MTHFR genotypes in 220 newborn and 222 elderly 80-108-year-old Swedes. In the newborn and elderly, the allele frequency, of the C677T/MTHFR mutation was 29.1 and 27.0% and the mutant homozygote frequency was 10.0 and 9.5%, respectively. In a meta analysis of the present and three previous studies including a total of 1388 elderly and 1415 younger subjects, the odds ratio (OR) representing the likelihood of the TT genotype to attain old age relative to the CC genotype was 0.87 (95% confidence interval (CI), 0.69-1.11) and relative to both the CC and CT genotypes was 0.83 (95% CI, 0.66-1.04). This finding does not suggest that the C677T/MTHFR mutation is a strong risk factor for diseases frequently leading to premature death.
Notes
Comment In: Atherosclerosis. 1999 Oct;146(2):395-710532696
PubMed ID
9862180 View in PubMed
Less detail

Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease.

https://arctichealth.org/en/permalink/ahliterature210337
Source
Circulation. 1996 Dec 15;94(12):3074-8
Publication Type
Article
Date
Dec-15-1996
Author
T G Deloughery
A. Evans
A. Sadeghi
J. McWilliams
W D Henner
L M Taylor
R D Press
Author Affiliation
Department of Medicine, Oregon Health Sciences University, Portland 97201-3098, USA. delought@ccmail.ohsu.edu
Source
Circulation. 1996 Dec 15;94(12):3074-8
Date
Dec-15-1996
Language
English
Publication Type
Article
Keywords
Adult
Age of Onset
Aged
Base Sequence
Blood Donors
Canada
DNA Primers
Gene Frequency
Genotype
Homocysteine - metabolism
Homozygote
Humans
Infant, Newborn
Methylenetetrahydrofolate Reductase (NADPH2)
Middle Aged
Oxidoreductases Acting on CH-NH Group Donors - genetics
Point Mutation
Polymerase Chain Reaction
Reference Values
Regression Analysis
Vascular Diseases - genetics - physiopathology
Abstract
Increased homocysteine levels are a risk factor for atherosclerosis and its sequelae. A common genetic mutation in methylenetetrahydrofolate reductase (MTHFR), an enzyme required for efficient homocysteine metabolism, creates a thermolabile enzyme with reduced activity. We determined the prevalence of this mutation in many subjects with and without vascular disease and related it to homocysteine and folate levels.
DNA from 247 older subjects with vascular disease and 594 healthy subjects without vascular disease (in three different control groups) was screened for the MTHFR 677 C-to-T mutation. Within each group, 9% to 17% of the subjects were homozygous for this mutation, and the mutant allele frequency was 31% to 39%. The genotype distributions, homozygote frequencies, and allele frequencies did not differ significantly between the study groups. In the vascular disease subjects, despite significantly lower folate levels in MTHFR homozygotes, there was no significant difference in homocysteine levels among the MTHFR genotype groups. The negative slope of the regression line relating homocysteine and folate was significantly steeper for those with a homozygous MTHFR mutation compared with those without this mutation.
Although the thermolabile MTHFR mutation is very common, it does not appear to be a significant genetic risk factor for typical late-onset vascular disease. Because MTHFR homozygotes have increased homocysteine with low folate levels, this mutation may contribute to early-onset or familial vascular disease. The genotype dependence of the folate-homocysteine correlation further suggests that homozygotes for this mutation may have both an exaggerated hyperhomocysteinemic response to folic acid depletion and a better response to folic acid therapy.
PubMed ID
8989110 View in PubMed
Less detail

Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study.

https://arctichealth.org/en/permalink/ahliterature210780
Source
J Clin Invest. 1996 Nov 1;98(9):2174-83
Publication Type
Article
Date
Nov-1-1996
Author
A B Guttormsen
P M Ueland
I. Nesthus
O. Nygård
J. Schneede
S E Vollset
H. Refsum
Author Affiliation
Department of Clinical Biology, University of Bergen, Norway.
Source
J Clin Invest. 1996 Nov 1;98(9):2174-83
Date
Nov-1-1996
Language
English
Publication Type
Article
Keywords
Adult
Aged
Female
Folic Acid - blood - therapeutic use
Gene Frequency
Homocysteine - blood
Homozygote
Humans
Male
Mass Screening
Methylenetetrahydrofolate Reductase (NADPH2)
Middle Aged
Norway
Odds Ratio
Oxidoreductases Acting on CH-NH Group Donors - genetics
Point Mutation
Vitamin B 12 - therapeutic use
Vitamin B 12 Deficiency - complications
Abstract
From 1992-93, we screened 18,043 subjects, aged 40-67 yr, and found 67 cases (0.4%) with total plasma homocysteine (tHcy) > or = 40 micromol/liter. Compared to 329 controls, the cases had lower plasma folate and cobalamin levels, lower intake of vitamin supplements, consumed more coffee, and were more frequently smokers. Homozygosity for the C677T mutation in the methylenetetrahydrofolate reductase gene was observed in 73.1% of the cases and 10.2% of the controls. Only seven cases with cobalamin deficiency and one with homocystinuria received specific therapeutic instructions. 2 yr after the screening, 58 subjects were reinvestigated. 41 still had tHcy > 20 micromol/liter, and in 37 of these, intervention with low dose folic acid (0.2 mg/d) was started. Notably, 34 of 37 (92%) had homozygosity for the C677T mutation. Plasma tHcy was reduced in all but two after 7 wk, and became normal within 7 mo in 21 of 37 subjects. Most of the remaining subjects obtained a normal tHcy level with 5 mg/d of folic acid. We conclude that most subjects with hyperhomocysteinemia > or = 40 micromol/liter in the general population have the C677T mutation combined with low folate status. Daily supplement of low dose folic acid will reduce and often normalize their tHcy level.
Notes
Cites: Clin Chem. 1970 Dec;16(12):1016-215481561
Cites: QJM. 1996 Aug;89(8):571-78935478
Cites: Metabolism. 1985 Nov;34(11):1073-73932819
Cites: Scand J Clin Lab Invest. 1988 May;48(3):215-213375778
Cites: Am J Hum Genet. 1988 Oct;43(4):414-213177384
Cites: Clin Chem. 1989 Sep;35(9):1921-72776317
Cites: Atherosclerosis. 1990 Feb;81(1):51-602407253
Cites: Am J Clin Nutr. 1992 Jun;55(6):1154-601595588
Cites: Annu Rev Nutr. 1992;12:279-981503807
Cites: Am J Clin Nutr. 1993 Jan;57(1):47-538416664
Cites: Clin Chem. 1993 Feb;39(2):263-718432015
Cites: Clin Chem. 1993 Sep;39(9):1764-798375046
Cites: Circulation. 1993 Oct;88(4 Pt 1):1463-98403293
Cites: FASEB J. 1993 Nov;7(14):1344-537901104
Cites: Arterioscler Thromb. 1994 Mar;14(3):465-708123653
Cites: JAMA. 1993 Dec 8;270(22):2693-88133587
Cites: Am J Clin Nutr. 1994 May;59(5):1033-98172087
Cites: BMJ. 1994 Jun 4;308(6942):14998019287
Cites: J Nutr. 1994 Jul;124(7):1072-808027858
Cites: J Nutr. 1994 Oct;124(10):1927-337931701
Cites: Am J Hum Genet. 1995 Jan;56(1):142-507825569
Cites: Anal Chem. 1995 Mar 1;67(5):812-97762817
Cites: Clin Chem. 1995 Jul;41(7):1033-77600684
Cites: Lancet. 1995 Jul 8;346(8967):85-97603218
Cites: Nat Genet. 1995 May;10(1):111-37647779
Cites: JAMA. 1995 Oct 4;274(13):1049-577563456
Cites: J Nutr. 1995 Oct;125(10):2717-257562109
Cites: Lancet. 1995 Oct 21;346(8982):1070-17564788
Cites: JAMA. 1995 Nov 15;274(19):1526-337474221
Cites: Lancet. 1995 Nov 25;346(8987):1395-87475822
Cites: Am J Hum Genet. 1996 Jan;58(1):17-208554053
Cites: Am J Hum Genet. 1996 Jan;58(1):35-418554066
Cites: Circulation. 1996 Jan 1;93(1):7-98616944
Cites: QJM. 1995 Nov;88(11):763-68542260
Cites: Am J Clin Nutr. 1996 Feb;63(2):194-2028561060
Cites: Anal Biochem. 1995 Nov 1;231(2):359-658594986
Cites: Clin Chem. 1996 Apr;42(4):630-68605683
Cites: Clin Chem. 1970 Dec;16(12):1022-75481562
PubMed ID
8903338 View in PubMed
Less detail

Examinations of methylenetetrahydrofolate reductase C677T and A1298C mutations--and in utero viability.

https://arctichealth.org/en/permalink/ahliterature193004
Source
Am J Hum Genet. 2001 Nov;69(5):1150-3
Publication Type
Article
Date
Nov-2001

Exploring the effects of methylenetetrahydrofolate reductase gene variants C677T and A1298C on the risk of orofacial clefts in 261 Norwegian case-parent triads.

https://arctichealth.org/en/permalink/ahliterature30903
Source
Am J Epidemiol. 2003 Jun 15;157(12):1083-91
Publication Type
Article
Date
Jun-15-2003
Author
Astanand Jugessur
Allen J Wilcox
Rolv T Lie
Jeffrey C Murray
Jack A Taylor
Arve Ulvik
Christian A Drevon
Hallvard A Vindenes
Frank E Abyholm
Author Affiliation
Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway. Astanand.Jugessur@molmed.uib.no
Source
Am J Epidemiol. 2003 Jun 15;157(12):1083-91
Date
Jun-15-2003
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Alanine - genetics
Case-Control Studies
Cleft Lip - enzymology - genetics - prevention & control
Cleft Palate - enzymology - genetics - prevention & control
Cysteine - genetics
Female
Folic Acid - administration & dosage
Genetic Predisposition to Disease
Haplotypes
Humans
Male
Methylenetetrahydrofolate Reductase (NADPH2)
Norway - epidemiology
Oxidoreductases Acting on CH-NH Group Donors - genetics
Polymerase Chain Reaction
Registries
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Risk factors
Threonine - genetics
Variation (Genetics)
Abstract
Folic acid and the methylenetetrahydrofolate reductase (MTHFR) gene have both been implicated in the etiology of orofacial clefts. The authors selected 261 case-parent triads (173 cases with cleft lip with or without cleft palate (CL/P) and 88 cases with cleft palate only (CPO)) from a Norwegian population-based study of orofacial clefts (May 1996-1998). A case-parent triad design was used to examine whether MTHFR variants C677T and A1298C, and their haplotypes, are risk factors for orofacial clefts. Among CL/P cases, the child's genotype at C677T or A1298C did not influence the risk. However, children of mothers carrying the C677T variant allele had a lower risk of CL/P. For CPO, children carrying the C677T variant allele had about a twofold increased risk, whereas the mother's genotypes did not contribute to the risk. The haplotype-based transmission/disequilibrium test showed that except for 677T/1298A (p = 0.06), none of the other haplotypes showed evidence of excess transmission to the offspring. The authors also explored interaction of C677T with maternal use of folic acid among children with CPO. Surprisingly, the risk associated with the child's carrying either CT or TT was higher (fourfold) when the mother used folic acid. These findings suggest a possible role of MTHFR and folic acid in the causation of orofacial clefts, but the strength and direction of these effects remain to be clarified.
PubMed ID
12796044 View in PubMed
Less detail

Folate intake, plasma folate and homocysteine status in a random Finnish population.

https://arctichealth.org/en/permalink/ahliterature186911
Source
Eur J Clin Nutr. 2003 Jan;57(1):81-8
Publication Type
Article
Date
Jan-2003
Author
G. Alfthan
M S Laurinen
L M Valsta
T. Pastinen
A. Aro
Author Affiliation
Department of Health and Functional Capacity, National Public Health Institute, Mannerheimintie, Helsinki, Finland. george.alfthan@ktl.fi
Source
Eur J Clin Nutr. 2003 Jan;57(1):81-8
Date
Jan-2003
Language
English
Publication Type
Article
Keywords
Adult
Aged
Biological Markers - blood
Diet
Dietary Supplements
Female
Finland
Folic Acid - administration & dosage - blood
Genotype
Homocysteine - blood
Homozygote
Humans
Male
Methylenetetrahydrofolate Reductase (NADPH2)
Middle Aged
Nutritional Status
Oxidoreductases Acting on CH-NH Group Donors - genetics
Vitamin B 12 - blood
Abstract
To assess the folate status of Finnish adults using plasma folate and homocysteine as biomarkers and to evaluate dietary and supplementary folate intakes.
Plasma folate, vitamin B(12) and total homocysteine (tHcy) were determined in a random sample of 643 subjects aged 25-74 y living in the Helsinki area. The methylenetetrahydrofolate reductase (MTHFR)-genotypes were analyzed from a subsample (n=394). Dietary intake data by 24 h recall and use of vitamin supplements were collected.
Plasma folate was normal (>/=5 nmol/l) in 99% of subjects and optimal (>/=8 nmol/l) in terms of a minimum tHcy in 90%. Mean plasma folate of non-supplement users was 13.7 and 12.9 nmol/l and tHcy 11.3 and 9.2 micro mol/l for men and women, respectively. Elevated tHcy (>14 micro mol/l) was found in 11% of subjects. Homozygote frequency for MTHFR genotype TT was 5.0% and their plasma tHcy was 14.8 micro mol/l compared to the mean of the other subjects, 10.5 micro mol/l, P
PubMed ID
12548301 View in PubMed
Less detail

20 records – page 1 of 2.